Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

The Lancet Oncology , Volume 17 (5): 13 – Jun 13, 2017

Loading next page...
 
/lp/pubmed/afatinib-versus-gefitinib-as-first-line-treatment-of-patients-with-ggrmJEK0hG

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1470-2045
DOI
10.1016/S1470-2045(16)30033-X
pmid
27083334

Abstract

Journal

The Lancet OncologyPubmed

Published: Jun 13, 2017

There are no references for this article.